Mirxes Holding Co., Ltd. operates as an investment holding company. The company employs 347 full-time employees The company went IPO on 2025-05-23. The company develops and commercializes accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases. Its segments include Infectious diseases and Early detection and precision multi-omics. Its solutions include cancer screening; clinical sequencing; cancer treatment selection, and infectious diseases. Its core product (namely, GASTROClear), two other commercialized products (namely, LUNGClear and Fortitude), and six product candidates at pre-clinical stage. GASTROClear is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. LUNGClear, its lung cancer screening product candidate, is a detection panel consisting of miRNA biomarkers discovered and verified in multi-center studies. The company offers complete COVID-19 testing solutions.
02629.HK stock price ended at $44.1 on 星期四, after rising 3.76%
On the latest trading day Jan 08, 2026, the stock price of 02629.HK rose by 3.76%, climbing from $42.50 to $44.10. Throughout the session, the stock experienced a volatility of 6.41%, with prices fluctuating between a daily low of $41.82 and a high of $44.50. Alongside this price increase, trading volume also rose by 65.9K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 403.5K shares were traded, amounting to a market value of approximately $12.1B.